NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $1.82 +0.02 (+0.83%) Closing price 03:58 PM EasternExtended Trading$1.80 -0.01 (-0.55%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Senti Biosciences Stock (NASDAQ:SNTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Senti Biosciences alerts:Sign Up Key Stats Today's Range$1.77▼$1.8650-Day Range$1.80▼$3.8452-Week Range$1.52▼$16.94Volume67,561 shsAverage Volume180,990 shsMarket Capitalization$47.34 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company Overview Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read More Senti Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreSNTI MarketRank™: Senti Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 637th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSenti Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Senti Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Senti Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.66% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 114.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.66% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 114.96%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentSenti Biosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Senti Biosciences this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.12% of the stock of Senti Biosciences is held by insiders.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Stock News HeadlinesSenti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comSenti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.July 30 at 2:00 AM | Porter & Company (Ad)Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience ForumJuly 21, 2025 | globenewswire.comSenti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of DirectorsJuly 18, 2025 | globenewswire.comNASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.comJuly 3, 2025 | investing.comSNTI - Senti Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMSenti Bio Participates in Nasdaq Amplify Spotlight SeriesJune 30, 2025 | globenewswire.comSee More Headlines SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $3.51 at the beginning of the year. Since then, SNTI shares have decreased by 47.4% and is now trading at $1.8460. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.85. The firm earned $1.30 million during the quarter, compared to analysts' expectations of $1.30 million. When did Senti Biosciences' stock split? Shares of Senti Biosciences reverse split before market open on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Senti Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI). Company Calendar Last Earnings5/06/2025Today7/30/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for Senti Biosciences$8.50 High Price Target$12.00 Low Price Target$5.00 Potential Upside/Downside+360.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($10.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-177.24% Return on Assets-67.38% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio4.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book0.35Miscellaneous Outstanding Shares26,081,000Free Float25,267,000Market Cap$48.15 million OptionableNot Optionable Beta2.09 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SNTI) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.